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Mathematics

Applications of Mixed Effects Modeling
in Observational Studies and Clinical Trials
for Alzheimer’s Disease
Karthik Rohatgi
Mentor: Ed Spitznagel
White matter hyperintensity (WMH) is increasingly recognized as a core pathology
of Alzheimer's Disease (AD). However, the association between WMH and mutations
conferring AD (irrespective of actual AD diagnosis) is less well known. We studied this
issue through linear mixed effects modelling, using data from the Dominantly Inherited
Alzheimer’s Network (n = 456). The model confirmed that mutation carriers have greater
WMH than non-carriers after controlling for other predictors (t = 6.23, p < 0.0001).
We also used three different methods (ANCOVA-like model, unadjusted and fully
adjusted linear mixed models) to calculate rate of change (ROC) in WMH. Loess
regression was used throughout to qualitatively explore relationships in the data. Using
the fully adjusted model, we determined that the ROC in WMH significantly exceeds
zero at Baseline EYO of -23.56 years for non-carriers, and at least -25 years for carriers.
Percentile bootstrap confidence intervals were also obtained for these EYO points. Our
findings suggest that medical intervention is necessary for mutation carriers several
decades before symptom onset.
More generally, we also sought to determine an effective linear model for a
randomized controlled trial (RCT) with dose escalation at a fixed time point. To do this,
we simulated 1,000 clinical trials, used 4 different mixed models for repeated measures
(MMRM) to analyze each trial, and then calculated the statistical power of each model.
The model which included a continuous dose variable interacting with time was found
to have the highest power (0.534).
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